Maksim Mamonkin

Experts Arnon Nagler, MD and Maksim Mamonkin, PhD discuss the growing role of immunotherapy in the treatment of B-cell acute lymphoblastic leukemia (B-ALL). They explore the use of novel immunotherapies like CAR-T cells, antibody-drug conjugates, and monoclonal antibodies, as well as the possibility of moving away from stem cell transplantation. Topics covered include targeting CD7 in T-ALL, chemotherapy-free regimens, and the future of ALL treatment.

Experts discuss recent updates in CAR-T and cellular therapy, including T cell engineering, CRISPR gene disruption, mesenchymal stem cells for COVID-19 pneumonia, and CAR-T cell therapy in challenging patient populations. They also analyze studies on CAR-T cell therapy, comparing management of toxicities, eligibility criteria, and durable responses. Additionally, they explore a comparison study between exocaptogen, CIBMTR, and T-stinlucil, and the potential of gene-edited effector cell therapy.